Innostars Talks: Stockholm3 — Diagnosing prostate cancer faster

Did you know that in 2018, one in five men was diagnosed with prostate cancer?  Currently, the PSA test is used as a biomarker of the disease, but it has low sensitivity and specificity, increased risk of false-positives and it cannot differentiate between benign and aggressive cancer.  The Stockholm3 test, on the other hand, is a blood test that can predict the risk of aggressive disease and lower the risk of unnecessary biopsies by 50 per cent. It is a joint effort between the Karolinska Institute, Thermofisher Scientific and Synlab.  In this first episode, Daniela Dias-Santos talks to Martin Steinberg, Stockholm3 Project Leader at Karolinska Institute, and Per Matsson, CTO at Phadia, Thermofisher Scientific. Both are EIT Health partners. They tell us how to involve partners in an innovative project. Don't forget to visit our website at eithealth.eu/in-your-region/innostars/ for more information about our new programmes, calls for proposals and applications and events.